![Would the Recommended Dose Have Been Different Using Novel Dose-Finding Designs? Comparing Dose-Finding Designs in Published Trials | JCO Precision Oncology Would the Recommended Dose Have Been Different Using Novel Dose-Finding Designs? Comparing Dose-Finding Designs in Published Trials | JCO Precision Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/po/2021/po.2021.5/po.21.00136/20210611/images/large/po.21.00136t2.jpeg)
Would the Recommended Dose Have Been Different Using Novel Dose-Finding Designs? Comparing Dose-Finding Designs in Published Trials | JCO Precision Oncology
![On Biostatistics and Clinical Trials: Dose Limiting Toxicity (DLT) and Common Toxicity Criteria (CTC) / Common Terminology Criteria for Adverse Events (CTCAE) On Biostatistics and Clinical Trials: Dose Limiting Toxicity (DLT) and Common Toxicity Criteria (CTC) / Common Terminology Criteria for Adverse Events (CTCAE)](http://3.bp.blogspot.com/-wuebrZQwQk4/VLshyehJGII/AAAAAAAAAZY/DO9uJrwZ3l0/s1600/untitled.bmp)
On Biostatistics and Clinical Trials: Dose Limiting Toxicity (DLT) and Common Toxicity Criteria (CTC) / Common Terminology Criteria for Adverse Events (CTCAE)
![Chemotherapy dose per kilogram lean body mass increased dose-limiting toxicity event in male head and neck cancer with taxane and platinum-based induction therapy | BMC Cancer | Full Text Chemotherapy dose per kilogram lean body mass increased dose-limiting toxicity event in male head and neck cancer with taxane and platinum-based induction therapy | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-022-10152-y/MediaObjects/12885_2022_10152_Fig2_HTML.png)
Chemotherapy dose per kilogram lean body mass increased dose-limiting toxicity event in male head and neck cancer with taxane and platinum-based induction therapy | BMC Cancer | Full Text
TAT 2011 presentation: Definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents
![A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors | Scientific Reports A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-021-82671-w/MediaObjects/41598_2021_82671_Fig2_HTML.png)
A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors | Scientific Reports
![Liposomal Cisplatin Dose Escalation for Determining the Maximum Tolerated Dose and Dose-limiting Toxicity: A Phase I Study | Anticancer Research Liposomal Cisplatin Dose Escalation for Determining the Maximum Tolerated Dose and Dose-limiting Toxicity: A Phase I Study | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/30/4/1317/T3.medium.gif)
Liposomal Cisplatin Dose Escalation for Determining the Maximum Tolerated Dose and Dose-limiting Toxicity: A Phase I Study | Anticancer Research
![Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents – Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents – Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group](https://ars.els-cdn.com/content/image/1-s2.0-S0959804914006352-gr1.jpg)
Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents – Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group
![Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy. | Semantic Scholar Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/d394f49428f9b68ce99503f28396150c7de8bff8/3-Table2-1.png)
Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy. | Semantic Scholar
![Nutrients | Free Full-Text | Association of Low Handgrip Strength with Chemotherapy Toxicity in Digestive Cancer Patients: A Comprehensive Observational Cohort Study (FIGHTDIGOTOX) Nutrients | Free Full-Text | Association of Low Handgrip Strength with Chemotherapy Toxicity in Digestive Cancer Patients: A Comprehensive Observational Cohort Study (FIGHTDIGOTOX)](https://pub.mdpi-res.com/nutrients/nutrients-14-04448/article_deploy/html/images/nutrients-14-04448-g001.png?1666595552)
Nutrients | Free Full-Text | Association of Low Handgrip Strength with Chemotherapy Toxicity in Digestive Cancer Patients: A Comprehensive Observational Cohort Study (FIGHTDIGOTOX)
![On Biostatistics and Clinical Trials: Dose Limiting Toxicity (DLT) and Common Toxicity Criteria (CTC) / Common Terminology Criteria for Adverse Events (CTCAE) On Biostatistics and Clinical Trials: Dose Limiting Toxicity (DLT) and Common Toxicity Criteria (CTC) / Common Terminology Criteria for Adverse Events (CTCAE)](http://3.bp.blogspot.com/-wuebrZQwQk4/VLshyehJGII/AAAAAAAAAZY/DO9uJrwZ3l0/w1200-h630-p-k-no-nu/untitled.bmp)
On Biostatistics and Clinical Trials: Dose Limiting Toxicity (DLT) and Common Toxicity Criteria (CTC) / Common Terminology Criteria for Adverse Events (CTCAE)
![Designing Dose-Finding Phase I Clinical Trials: Top 10 Questions That Should Be Discussed With Your Statistician | JCO Precision Oncology Designing Dose-Finding Phase I Clinical Trials: Top 10 Questions That Should Be Discussed With Your Statistician | JCO Precision Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/po/2021/po.2021.5/po.20.00379/20210128/images/large/po.20.00379t1.jpeg)
Designing Dose-Finding Phase I Clinical Trials: Top 10 Questions That Should Be Discussed With Your Statistician | JCO Precision Oncology
![Study protocol: phase 1 dose escalating study of Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) with oxaliplatin in peritoneal metastasis Study protocol: phase 1 dose escalating study of Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) with oxaliplatin in peritoneal metastasis](https://www.degruyter.com/document/doi/10.1515/pp-2018-0118/asset/graphic/j_pp-2018-0118_fig_001.jpg)